Isomorphic Labs raises $5 billion in Series C funding
The DeepMind spinout secured $5 billion from investors including Greenoaks and Sequoia to advance oncology and immunology drug candidates to clinical trials.
- Field
- industry news
- What they did
- Isomorphic Labs, an AI drug-discovery platform spun out of DeepMind, raised $5 billion in a Series C funding round to move its drug candidates into clinical trials.
- Why it matters
- The funding will support the company's AI-driven drug design engine, which has already shown positive preclinical results in oncology and immunology through partnerships with major pharma companies.
#isomorphic labs#funding#clinical trials#drug discovery#deepmind



